SV2007002429A - Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias - Google Patents

Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias

Info

Publication number
SV2007002429A
SV2007002429A SV2006002429A SV2006002429A SV2007002429A SV 2007002429 A SV2007002429 A SV 2007002429A SV 2006002429 A SV2006002429 A SV 2006002429A SV 2006002429 A SV2006002429 A SV 2006002429A SV 2007002429 A SV2007002429 A SV 2007002429A
Authority
SV
El Salvador
Prior art keywords
pgd2
treatment
inflammatory diseases
receiver antagonists
antagonists
Prior art date
Application number
SV2006002429A
Other languages
English (en)
Inventor
Jeremy D Little
Shomir Ghosh
Sean Harrison
Amy M Elder
Christelle C Renou
Original Assignee
Millenium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36593677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2007002429(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millenium Pharmaceuticals Inc filed Critical Millenium Pharmaceuticals Inc
Publication of SV2007002429A publication Critical patent/SV2007002429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBEN INHIBIDORES DE CRTH2 REPRESENTADOS POR LA FORMULA ESTRUCTURAL (I) : (VER FORMULA) LOS VALORES DE LAS VARIABLES DE LA FORMULA ESTRUCTURAL (I) SE PROPORCIONAN EN ESTE DOCUMENTO
SV2006002429A 2005-02-24 2006-02-24 Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias SV2007002429A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65592705P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
SV2007002429A true SV2007002429A (es) 2007-02-19

Family

ID=36593677

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002429A SV2007002429A (es) 2005-02-24 2006-02-24 Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias

Country Status (26)

Country Link
US (1) US7951950B2 (es)
EP (1) EP1861372A1 (es)
JP (1) JP2008543726A (es)
KR (1) KR20070114762A (es)
CN (1) CN101146776A (es)
AR (1) AR052580A1 (es)
AU (1) AU2006216713A1 (es)
BR (1) BRPI0608553A2 (es)
CA (1) CA2598133A1 (es)
CR (1) CR9378A (es)
DO (1) DOP2006000054A (es)
GT (1) GT200600093A (es)
IL (1) IL185422A0 (es)
MA (1) MA29330B1 (es)
MX (1) MX2007010215A (es)
NI (1) NI200700221A (es)
NO (1) NO20074388L (es)
PE (1) PE20061013A1 (es)
RU (1) RU2007135224A (es)
SV (1) SV2007002429A (es)
TN (1) TNSN07325A1 (es)
TW (1) TW200640869A (es)
UA (1) UA90706C2 (es)
UY (1) UY29397A1 (es)
WO (1) WO2006091674A1 (es)
ZA (1) ZA200707498B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITVA20050050A1 (it) * 2005-08-05 2007-02-06 Lamberti Spa Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita'
WO2007130353A2 (en) * 2006-05-01 2007-11-15 Johns Hopkins University Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress
PT2327693E (pt) 2007-12-14 2012-07-24 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
CN102099342B (zh) 2008-07-15 2013-07-10 霍夫曼-拉罗奇有限公司 氨基四氢吲唑基乙酸类
CA2730390A1 (en) 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
EP2321266A2 (en) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Substituted aminotetralines
WO2010018113A2 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
KR20110071122A (ko) 2008-11-17 2011-06-28 에프. 호프만-라 로슈 아게 나프틸아세트산
MX2011005120A (es) 2008-11-17 2011-05-30 Hoffmann La Roche Acidos naftilaceticos.
CA2739725A1 (en) 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids used as crth2 antagonists or partial agonists
JP5800898B2 (ja) 2010-07-05 2015-10-28 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
MX2013014900A (es) * 2011-06-17 2014-02-17 Merck Sharp & Dohme Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de la molecula receptora homologa quimioatrayente expresada en celulas t auxiliares de tipo 2.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US8691993B2 (en) * 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
JP2015520752A (ja) * 2012-05-11 2015-07-23 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体
CN104271572A (zh) * 2012-05-11 2015-01-07 艾伯维公司 用作nampt抑制剂的噻唑羧酰胺衍生物
US9296723B2 (en) * 2012-05-11 2016-03-29 Abbvie Inc. NAMPT inhibitors
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2015074064A2 (en) 2013-11-18 2015-05-21 Bair Kenneth W Tetrahydroquinoline compositions as bet bromodomain inhibitors
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
US9727784B2 (en) * 2014-06-03 2017-08-08 Digitalglobe, Inc. Some automated and semi-automated tools for linear feature extraction in two and three dimensions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
CA2116334A1 (en) 1992-07-02 1994-01-20 Hidenori Ogawa Oxytocin antagonist
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
WO2000006153A1 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6048873A (en) 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
KR100731566B1 (ko) 1999-10-14 2007-06-22 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
MXPA02006617A (es) 2000-01-03 2004-09-10 Pharmacia Corp Dihidrobenzopiranos, dihidrobenzotiopiranos, y tetrahidroquinolinas para el tratamiento de desordenes mediados por cox-2.
DE10005302A1 (de) 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
AU2001246844A1 (en) 2000-04-07 2001-10-23 Takeda Chemical Industries Ltd. Soluble beta amyloid precursor protein secretion promoters
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2002053557A (ja) 2000-08-14 2002-02-19 Japan Tobacco Inc アポリポ蛋白ａ−ｉ産生促進薬
AU8647101A (en) 2000-08-29 2002-03-13 Allergan Sales Inc Compounds having activity as inhibitors of cytochrome p450rai
US6291677B1 (en) 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
WO2002022585A1 (fr) 2000-09-14 2002-03-21 Kaken Pharmaceutical Co., Ltd. Composes de tetrahydroquinoline
DE10103657A1 (de) 2001-01-27 2002-08-01 Henkel Kgaa Neue Kupplerkomponente für Oxidationsmittel
SE0101161D0 (sv) 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
HU225777B1 (en) 2001-04-30 2007-08-28 Pfizer Prod Inc Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
US20050228016A1 (en) 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
ES2263015T3 (es) 2002-10-21 2006-12-01 Warner-Lambert Company Llc Derivados de tetrahidroquinolina como antagonistas de crth2.
WO2004052863A1 (ja) 2002-12-06 2004-06-24 Kyowa Hakko Kogyo Co., Ltd. 抗炎症剤
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
BRPI0408897A (pt) * 2003-03-28 2006-04-18 Pfizer Prod Inc derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
US20050038070A1 (en) * 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
AR048528A1 (es) 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.

Also Published As

Publication number Publication date
US20060241109A1 (en) 2006-10-26
GT200600093A (es) 2006-10-19
BRPI0608553A2 (pt) 2010-01-12
NI200700221A (es) 2008-05-09
US7951950B2 (en) 2011-05-31
TW200640869A (en) 2006-12-01
MA29330B1 (fr) 2008-03-03
CN101146776A (zh) 2008-03-19
UY29397A1 (es) 2006-10-02
EP1861372A1 (en) 2007-12-05
AR052580A1 (es) 2007-03-21
RU2007135224A (ru) 2009-03-27
ZA200707498B (en) 2008-11-26
CA2598133A1 (en) 2006-08-31
CR9378A (es) 2008-01-21
IL185422A0 (en) 2008-01-06
NO20074388L (no) 2007-11-20
MX2007010215A (es) 2007-11-07
KR20070114762A (ko) 2007-12-04
JP2008543726A (ja) 2008-12-04
PE20061013A1 (es) 2006-10-13
AU2006216713A1 (en) 2006-08-31
DOP2006000054A (es) 2006-08-31
TNSN07325A1 (en) 2008-12-31
UA90706C2 (ru) 2010-05-25
WO2006091674A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
SV2007002429A (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
EA201171081A1 (ru) Производные индола в качестве антагонистов рецептора crth2
CU20110078A7 (es) Compuestos de carbazol
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
CY1115944T1 (el) Παραγωγα 4-(ινδολ-7-υλοκαρβονυλαμινομεθυλο)κυκλοεξανοκαρβοξυλικου οξεος ως ανταγωνιστες του ερ4 υποδοχεα χρησιμοι για την αντιμετωπιση χρονιας νεφρικης ανεπαρκειας ή διαβητικης νεφροπαθειας
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
CR11690A (es) Pirazolo (3,4-b) piridinas como inhibidores de raf
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
ECSP099786A (es) Pirazol amidas de ácido carboxílico útiles como microbicidas
CR20110452A (es) Inhibidores de la poli (adp-ribosa) polimerasa (parp)
SV2010003458A (es) Compuestos y metodos para modular el receptor farnesoide x (fxr)
SV2010003714A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CO6290757A2 (es) N-(2(hetarl)ari)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
UY32713A (es) Nuevos agentes antihelmínticos heterocíclicos y su uso.
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos